Deferoxamine Other names: Desferoxamine B Desferrioxamine DFOA DFB Desferrioxamine B Desferal DFO-B

Chemical formula: C₂₅H₄₈N₆O₈ Molecular mass: 560.684 g/mol PubChem compound: 2973

Therapeutic indications

Deferoxamine is indicated for:

Chronic iron overload

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Treatment for chronic iron overload, e.g.

transfusional haemosiderosis in patients receiving regular transfusions e.g. thalassaemia major
primary and secondary haemochromatosis in patients in whom concomitant disorders (e.g. severe anaemia, hypoproteinaemia, renal or cardiac failure) preclude phlebotomy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

20-60 mg/kg/day based on ferritin levels

20-60 mg/kg/day based on ferritin levels

20-60 mg/kg/day based on ferritin levels

Acute iron poisoning

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Poisoning by iron

For this indication, competent medicine agencies globally authorize below treatments (click for details):

80 mg/kg in a 24 hour period

1 g once

2 g once

Diagnosis of iron storage disease and certain anaemias

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Hemochromatosis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

500 mg once

Aluminium overload in patients with end stage renal failure

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Aluminum and/or aluminum compound poisoning and additionally Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

For this indication, competent medicine agencies globally authorize below treatments (click for details):

5 mg/kg once a week

5 mg/kg once a week

5 mg/kg once a week

Diagnosis of aluminium overload in patients with end stage renal failure

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Aluminum and/or aluminum compound poisoning and additionally Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

For this indication, competent medicine agencies globally authorize below treatments (click for details):

5mg/kg during the last 60' of the haemodialysis session

Contraindications

Deferoxamine is contraindicated in the following cases:

Lactation

Lactation

Gallium-67

Gallium ⁶⁷Ga citrate

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈